314 related articles for article (PubMed ID: 28477166)
1. The accuracy of
Tian F; Shen G; Deng Y; Diao W; Jia Z
Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.
Cheng X; Li Y; Liu B; Xu Z; Bao L; Wang J
Acta Radiol; 2012 Jul; 53(6):615-27. PubMed ID: 22734080
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of
Han S; Choi JY
Breast Cancer Res; 2020 Oct; 22(1):119. PubMed ID: 33129348
[TBL] [Abstract][Full Text] [Related]
5. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
6. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
Xiao Y; Wang L; Jiang X; She W; He L; Hu G
Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
[TBL] [Abstract][Full Text] [Related]
8. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
[TBL] [Abstract][Full Text] [Related]
9. ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.
Groheux D; Mankoff D; Espié M; Hindié E
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):983-993. PubMed ID: 26758726
[TBL] [Abstract][Full Text] [Related]
10. MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis.
Li H; Yao L; Jin P; Hu L; Li X; Guo T; Yang K
Breast; 2018 Aug; 40():106-115. PubMed ID: 29758503
[TBL] [Abstract][Full Text] [Related]
11. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
Liu Q; Wang C; Li P; Liu J; Huang G; Song S
Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
[TBL] [Abstract][Full Text] [Related]
12. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
[TBL] [Abstract][Full Text] [Related]
13. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic accuracy of F-18 FDG PET or PET/CT for detection of lymph node metastasis in clinically node negative head and neck cancer patients; A systematic review and meta-analysis.
Kim SJ; Pak K; Kim K
Am J Otolaryngol; 2019; 40(2):297-305. PubMed ID: 30473166
[TBL] [Abstract][Full Text] [Related]
15. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
[TBL] [Abstract][Full Text] [Related]
16. Combination of breast imaging parameters obtained from
Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
García Vicente AM; Amo-Salas M; Relea Calatayud F; Muñoz Sánchez Mdel M; Pena Pardo FJ; Jiménez Londoño GA; Álvarez Cabellos R; Espinosa Aunión R; Soriano Castrejón Á
Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
[TBL] [Abstract][Full Text] [Related]
18. Predictive Value of 18 F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer.
Ko WS; Kim SJ
Clin Nucl Med; 2023 Jul; 48(7):574-580. PubMed ID: 36976654
[TBL] [Abstract][Full Text] [Related]
19. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
[TBL] [Abstract][Full Text] [Related]
20. Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer.
Hulikal N; Gajjala SR; Kalawat T; Kadiyala S; Kottu R
Asian Pac J Cancer Prev; 2020 Jan; 21(1):93-98. PubMed ID: 31983170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]